For a study, researchers sought to provide 5-year findings from CheckMate 227 Part 1 in which nivolumab with ipilimumab, regardless of tumor programmed death ligand 1 (PD-L1) status, increased overall survival (OS) against chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC). Randomization involved adults with stage IV/recurrent NSCLC, without EGFR mutations or ALK … Continue reading Nivolumab Plus Ipilimumab Vs. Chemotherapy: Survival Outcome